SCHEMBL16619551

SCHEMBL16619551

CCCCCCCC/C=C\CCCCCCCC(=O)NC1CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.83
▸ KMT2A Q03164 2/20 0.83
▸ MEN1 O00255 1/20 0.83
▸ ALDH1A1 P00352 1/20 0.83
▸ HPGD P15428 1/20 0.83
▸ CNR2 P34972 5/20 0.68
▸ CNR1 P21554 2/20 0.68
▸ TRPV1 Q8NER1 2/20 0.68
▸ GNAI3 P08754 1/20 0.63
▸ GNAO1 P09471 1/20 0.63
▸ GNAI1 P63096 1/20 0.63
▸ TERT O14746 3/20 0.59
▸ PTPN1 P18031 3/20 0.59
▸ PPARG P37231 3/20 0.59
▸ PPARD Q03181 3/20 0.59
▸ PPARA Q07869 3/20 0.59
▸ BLM P54132 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ FABP4 P15090 2/20 0.59
▸ GMNN O75496 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619553 1.00 MAPT (0.83) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL14671455 0.94 MAPT (0.74) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL14671461 0.94 MAPT (0.74) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL14671339 0.94 MAPT (0.74) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL5016615 0.92 MAPT (0.80) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL5016654 0.92 MAPT (0.80) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL4982180 0.91 MEN1 (1.00) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL6517985 0.91 MEN1 (1.00) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL4982184 0.91 MEN1 (1.00) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL8361102 0.90 GNAI3 (0.75) MAPTKMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10674755-B2 Organic Compounds GIVAUDAN S.A. (CH) 2020-06-09 — — US disclosed
EP-3057448-B1 ORGANIC COMPOUNDS HAVING TASTE-MODIFYING PROPERTIES GIVAUDAN SA (CH) 2017-12-06 — — EP disclosed
US-20160242443-A1 Organic Compounds GIVAUDAN S.A. (CH) 2016-08-25 — — US disclosed
EP-3057448-A1 ORGANIC COMPOUNDS Givaudan S.A. (CH) 2016-08-24 — — EP disclosed
CN-105636459-A Organic compounds GIVAUDAN SA 2016-06-01 — — CN disclosed
WO-2015050534-A1 ORGANIC COMPOUNDS GIVAUDAN S.A. (CH) 2015-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10674755-B2 Organic Compounds C9, PRMT5, CBR3 MAPT 2961/4885KMT2A 1785/4885MEN1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback